Announced
Completed
Financials
Tags
Minority
Venture Capital
Cross Border
Friendly
Pharmaceuticals
Netherlands
Private Equity
drug discovery
Acquisition
Completed
Private
Synopsis
GV, a venture capital firm, F-Prime, a global venture capital firm, and Casdin Capital, an investment company, led a $49m Series A funding round in Leyden Labs, a developer of preventive medicines designed to target respiratory viruses. “The speed of development of vaccines during the current pandemic has been impressive, but major global health and economic challenges are evident. If we can develop products that provide immediate protection against existing, mutating and new viruses, we can prevent future pandemics, fight existing ones, and help people strive for a fantastic life. We pursue this critical and ambitious mission with a great team of seasoned and curious biotech leaders and scientists," Koenraad Wiedhaup, Leyden Labs Founder and CEO.
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.